Pacgen Biopharma IPOs on TSX

Pacgen Biopharmaceuticals Corp., a Vancouver-based biopharmaceutical company, has raised $7.1 million Canadian dollars ($6.1 million) through an initial public offering on the TSX Venture Exchange in Canada, according to Taiwan Economic News. The company, founded by a Taiwanese professor, is developing drugs for the treatment and prevention of infectious diseases and diseases of the immune system. Western Life Sciences Fund, L.P., managed by Lombard Life Sciences, is a large shareholder in the company